This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Volasertib
- DrugBank Accession Number
- DB12062
- Background
Volasertib has been used in trials studying the treatment of Leukemia, Neoplasms, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, and Leukemia, Monocytic, Acute, among others.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Volasertib (DB12062)
- Weight
- Average: 618.8126
Monoisotopic: 618.400587506 - Chemical Formula
- C34H50N8O3
- Synonyms
- Volasertib
- External IDs
- BI 6727
- BI-6727
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareDarbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Volasertib. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Volasertib. Methoxy polyethylene glycol-epoetin beta The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Volasertib. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Volasertib. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Volasertib trihydrochloride O72812O5MN 946161-17-7 JFEPFDDQDQBWIL-VCVQLDHKSA-N
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as pteridines and derivatives. These are polycyclic aromatic compounds containing a pteridine moiety, which consists of a pyrimidine fused to a pyrazine ring to form pyrimido(4,5-b)pyrazine.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Pteridines and derivatives
- Sub Class
- Not Available
- Direct Parent
- Pteridines and derivatives
- Alternative Parents
- Alpha amino acids and derivatives / Benzamides / Methoxyanilines / Anisoles / Phenoxy compounds / Benzoyl derivatives / Dialkylarylamines / Methoxybenzenes / Alkyl aryl ethers / Aminopyrimidines and derivatives show 12 more
- Substituents
- 1,4-diazinane / Alkyl aryl ether / Alpha-amino acid or derivatives / Amine / Amino acid or derivatives / Aminopyrimidine / Aniline or substituted anilines / Anisole / Aromatic heteropolycyclic compound / Azacycle show 32 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 6EM57086EA
- CAS number
- 755038-65-4
- InChI Key
- SXNJFOWDRLKDSF-STROYTFGSA-N
- InChI
- InChI=1S/C34H50N8O3/c1-6-28-33(44)39(4)29-20-35-34(38-31(29)42(28)22(2)3)37-27-14-9-24(19-30(27)45-5)32(43)36-25-10-12-26(13-11-25)41-17-15-40(16-18-41)21-23-7-8-23/h9,14,19-20,22-23,25-26,28H,6-8,10-13,15-18,21H2,1-5H3,(H,36,43)(H,35,37,38)/t25-,26-,28-/m1/s1
- IUPAC Name
- 4-{[(7R)-7-ethyl-5-methyl-6-oxo-8-(propan-2-yl)-5,6,7,8-tetrahydropteridin-2-yl]amino}-3-methoxy-N-[(1r,4r)-4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexyl]benzamide
- SMILES
- CC[C@H]1N(C(C)C)C2=NC(NC3=CC=C(C=C3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)=NC=C2N(C)C1=O
References
- General References
- Not Available
- External Links
- PubChem Compound
- 10461508
- PubChem Substance
- 347828371
- ChemSpider
- 26327706
- BindingDB
- 50402023
- ChEMBL
- CHEMBL1233528
- PDBe Ligand
- IBI
- Wikipedia
- Volasertib
- PDB Entries
- 3fc2 / 5v67 / 5vbr / 7lak / 7lej / 7n7n
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Acute Myeloid Leukemia (AML) 1 2 Completed Treatment Acute Myeloid Leukemia (AML) 1 2 Completed Treatment Neoplasms, Ovarian 1 2 Completed Treatment Neoplastic Disease 1 2 Completed Treatment Non-Small Cell Lung Carcinoma (NSCLC) 1 2 Terminated Treatment Acute Myeloid Leukemia (AML) / High-risk Myelodysplastic Syndrome (MDS) 1 1 Completed Treatment Acute Myeloid Leukemia (AML) 1 1 Completed Treatment Chronic Myelomonocytic Leukemia (CMML) / Myelodysplastic Syndromes (MDS) 1 1 Completed Treatment Leukemias / Neoplastic Disease 1 1 Completed Treatment Neoplastic Disease 8
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0664 mg/mL ALOGPS logP 4.65 ALOGPS logP 4.2 ChemAxon logS -4 ALOGPS pKa (Strongest Acidic) 12.25 ChemAxon pKa (Strongest Basic) 8.7 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 9 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 106.17 Å2 ChemAxon Rotatable Bond Count 10 ChemAxon Refractivity 178.34 m3·mol-1 ChemAxon Polarizability 72.64 Å3 ChemAxon Number of Rings 6 ChemAxon Bioavailability 1 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at October 20, 2016 21:17 / Updated at February 21, 2021 18:53